Triamcinolone

Active substance
Triamcinolone
Domain
Chronic immune diseases
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Other chronic immune diseases
Extended indication
Osteoarthritis van de knie

1. Product

Proprietary name
Zilretta
Manufacturer
Flexion
Mechanism of action
Corticosteroid
Route of administration
Intra-articular
Therapeutical formulation
Injection
Budgetting framework
Extramural (GVS)
Additional comments
Triamcinolone acetonide extended-release injectable suspension, a corticosteroid with anti-inflammatory and immunomodulating properties. Pipeline watch 12 januari 2018: Clinical benefits after repeat administration. Phase III Interim/Top-line Results.

2. Registration

Registration route
Centralised (EMA)
Submission date
2020
Expected Registration
2021
Orphan drug
No
Registration phase
Clinical trials
Additional comments
Betamethason, methylprednisolon, triamcinolonacetonide

3. Therapeutic value

Therapeutic value
Potential equal value
Substantiation
De werkgroep verwacht geen grote impact. De verwachting is dat dit een deel van de huidige behandelingen zal overnemen.
Duration of treatment
Not found
Dosage per administration
40 mg
References
NCT02357459
Additional comments
Eenmalige injectie

4. Expected patient volume per year

Patient volume

< 2,500

Market share is generally not included unless otherwise stated.

References
Voklsgezondheidenzorg.nl; NIVEL zorgregistraties eerste lijn; Barten et al.BMC Fam Pract 2015)
Additional comments
In 2016 werd naar schatting bij 54.900 mensen knieartrose gediagnostiseerd. De prevalentie in 2016 bedroeg 571.600 patiënten. In 5% van de gevallen wordt door de huisarts een intra-articulaire injectie met corticosteroïden toegediend. De verwachting is dat deze nieuwe formulering van triamcinolon bij een deel van deze gevallen zal worden ingezet.

5. Expected cost per patient per year

Cost
25
References
GIPdatabank
Additional comments
Vergoeding per gebruiker voor betamethason, methylprednisolon, triamcinolonacetonide in 2016 betreft €24,50

6. Potential total cost per year

Total cost

62,500

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

Indication extension
No

9. Other information

There is currently no futher information available.